IFN Activity Differentiation via Specific Gene Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately distinguish between type I and type II IFN activity in autoimmune rheumatic diseases, leading to inadequate understanding of IFN signatures and ineffective therapies, as they often rely on type I IFN-specific markers that cannot differentiate between the effects of type I and type II IFNs.
Innovation Solution
Development of specific probes and methods to quantify type I and type II IFN activity by analyzing markers such as MDA5, IFIT3, GBP1, GBP2, INDO, RARRES3, WARS, CXCL10, IL18BP, SERPING1, and GBP5, allowing for the differentiation of IFN-α and IFN-γ activity in tissue samples through protein and mRNA analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If type I IFN-specific markers are used for diagnosis, then detection simplicity is improved, but measurement precision deteriorates because they cannot differentiate between type I and type II IFN activity
Solution Approach 1:
The invention segments the IFN detection into two distinct marker sets: type I IFN-specific markers (e.g., ISG15, OAS1, IFIT1) and type II IFN-specific markers (e.g., GBP1, GBP2, CXCL10). This segmentation allows each marker set to specifically detect its corresponding IFN type, resolving the contradiction by enabling precise differentiation while maintaining detection simplicity through standardized assay procedures.
Solution Approach 2:
The invention applies local quality by selecting markers that are specifically induced by particular IFN types in specific cellular contexts. Type I IFN markers are selected for detecting type I IFN activity, while type II IFN markers are selected for detecting type II IFN activity. This localized specificity ensures accurate differentiation of IFN types without compromising the ease of operation through established molecular biology techniques.
2Ease of operation
If a single IFN signature is used for disease classification, then diagnostic simplicity is improved, but reliability deteriorates due to heterogeneous IFN pathway activation patterns
Solution Approach 1:
The invention segments disease classification into distinct subsets based on IFN type: type I IFN-driven diseases (e.g., SLE, dermatomyositis) and type II IFN-driven diseases (e.g., certain cases of rheumatoid arthritis, psoriasis). By using separate marker panels for each IFN type, the method reliably distinguishes between different disease subsets while maintaining diagnostic simplicity through a systematic approach to patient stratification.
Solution Approach 2:
The invention changes the diagnostic parameter from a single composite IFN signature to multiple specific parameters (individual marker expression levels for both type I and type II IFNs). This allows for more reliable disease subsetting by capturing the heterogeneity of IFN pathway activation patterns across different patients and disease types, while still providing a clear diagnostic framework.
3Adaptability or versatility
If type I IFN pathway inhibition is applied broadly, then treatment coverage is improved, but effectiveness deteriorates due to varying IFN pathway contributions across diseases
Solution Approach 1:
The invention segments therapy selection into type I IFN-targeted treatments (e.g., anti-IFN-α antibodies, JAK inhibitors for type I IFN signaling) and type II IFN-targeted treatments (e.g., anti-IFN-γ antibodies, JAK inhibitors for type II IFN signaling). By first determining which IFN type is driving the disease using the specific marker panels, clinicians can select the appropriate therapy, improving effectiveness while maintaining broad adaptability through this systematic classification approach.
Solution Approach 2:
The invention changes the therapeutic parameter from broad-spectrum IFN inhibition to targeted IFN pathway inhibition based on the specific IFN type identified through marker analysis. This ensures that patients receive therapy directed at the correct IFN pathway (type I or type II), improving treatment effectiveness while maintaining versatility in covering different disease types through the appropriate selection of targeted therapies.
Data Source
AI summary
The present inventors identified a subpopulation of genes induced by type I and type II IFNs in a human submandibular gland (HSG) epithelial cell line. Unexpectedly, it was found that the majority of genes that are highly up-regulated by IFN-α are also highly induced by IFN-γ. In contrast, there was a substantial group of genes that are highly induced by IFN-γ only. In target tissues, this identified subpopulation of genes and probes allow different IFN patterns to be discerned, enabling more precise molecular classification of patient subpopulations. The identified gene probes are useful for selecting and monitoring therapy, and for defining efficacy of novel agents in the autoimmune rheumatic diseases.